Selepressin
Clinical data | |
---|---|
ATC code |
|
Identifiers | |
| |
Synonyms | H-Cys(1)-Phe-Ile-hGln-Asn-Cys(1)-Pro-Orn(iPr)-Gly-NH2 |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
Chemical and physical data | |
Formula | C46H73N13O11S2 |
Molar mass | 1048.282 g/mol |
3D model (JSmol) | |
| |
|
Selepressin (INN) (code name FE-202158), also known as [Phe(2),Ile(3), Hgn(4),Orn(iPr)(8)]vasopressin) is a potent, highly selective, short-acting peptide full agonist of the vasopressin 1A receptor and analog of vasopressin which is under development by Ferring Pharmaceuticals for the treatment of vasodilatory hypotension in septic shock.[1][2][3][4]
References
- ↑ Jeremy I Levin (24 October 2014). Macrocycles in Drug Discovery. Royal Society of Chemistry. pp. 313–. ISBN 978-1-84973-701-2.
- ↑ Jean-Louis Vincent (23 September 2012). Annual Update in Intensive Care and Emergency Medicine 2012. Springer Science & Business Media. pp. 80–. ISBN 978-3-642-25716-2.
- ↑ J. L. Vincent (2 September 2008). Yearbook of Intensive Care and Emergency Medicine 2008. Springer Science & Business Media. pp. 427–. ISBN 978-3-540-77290-3.
- ↑ Laporte, R.; Kohan, A.; Heitzmann, J.; Wisniewska, H.; Toy, J.; La, E.; Tariga, H.; Alagarsamy, S.; Ly, B.; Dykert, J.; Qi, S.; Wisniewski, K.; Galyean, R.; Croston, G.; Schteingart, C. D.; Riviere, P. J.- M. (2011). "Pharmacological Characterization of FE 202158, a Novel, Potent, Selective, and Short-Acting Peptidic Vasopressin V1a Receptor Full Agonist for the Treatment of Vasodilatory Hypotension". Journal of Pharmacology and Experimental Therapeutics. 337 (3): 786–796. ISSN 0022-3565. PMID 21411496. doi:10.1124/jpet.111.178848.
This article is issued from
Wikipedia.
The text is licensed under Creative Commons - Attribution - Sharealike.
Additional terms may apply for the media files.